By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Aldeyra Therapeutics 

131 Hartwell Avenue

Lexington  Massachusetts  02421  U.S.A.
Phone: 781-761-4904 Fax: N/A


Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, NS2, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.




FOUNDERS: Thomas A. Jordan and John E. Dowling

CEO: Todd C. Brady

CMO: David J. Clark

CFO: Stephen Tulipano


Please click here for Aldeyra job opportunities..


Please click here for clinical trial information..

Key Statistics

Ownership: Public

Web Site: Aldeyra
Symbol: ALDX


Company News
Aldeyra (ALDX) Announces Last Patient Dosed In Dry Eye Disease Phase IIa Clinical Trial 7/18/2017 6:45:37 AM
Aldeyra (ALDX) To Present Novel Data On The Anti-Inflammatory Mechanism And Activity Of ADX-102 At The World Congress On Inflammation 2017 Annual Meeting 6/19/2017 6:15:53 AM
Aldeyra (ALDX) Schedules Conference Call And Webcast To Announce Results From Allergic Conjunctivitis Phase IIb Clinical Trial 6/14/2017 8:14:31 AM
Aldeyra (ALDX) Plummets As Eye Drug Misses Primary Endpoint In Phase IIb Test 6/14/2017 6:27:01 AM
Aldeyra (ALDX) Announces First Patient Enrolled In Dry Eye Disease Phase IIa Clinical Trial 6/6/2017 8:26:53 AM
Aldeyra (ALDX) Presents Noninfectious Anterior Uveitis Phase II Clinical Trial Data At Association for Research in Vision & Ophthalmology 2017 Annual Meeting 5/19/2017 6:48:32 AM
Aldeyra (ALDX) Provides Corporate Update And Announces First Quarter 2017 Financial Results 5/16/2017 6:12:17 AM
Aldeyra (ALDX) Schedules Webcast And Conference Call To Provide Corporate Update And First Quarter 2017 Financial Results 5/9/2017 12:06:55 PM
Aldeyra (ALDX) Announces First Patient Enrolled In Noninfectious Anterior Uveitis Phase III Clinical Trial 5/1/2017 8:17:09 AM
Aldeyra (ALDX) Receives Orphan Drug Designation From FDA For ADX-102 In Sjögren-Larsson Syndrome 4/21/2017 12:57:44 PM